The Biopharma and Neutraceutical Research team in ITT Dublin have been working for a number of years in the area of antimicrobial peptides. This research group has received substantial funding in the past from Strand 1 Strand III and HEA funded research projects. The HEA funding is part of a major collaborative research project with Dublin City University and NUI Maynooth through membership of the National Institute of Cellular Biotechnology in the area of microbial pathogenesis.
The BPNR research group was awarded Institute Research Status in 2005 in recognition of its research in this strategically important area. The mission of this Institute Research Centre is to provide a coordinated research and development base for the generation of novel and improved anti-microbial agents for application in the pharmaceutical and neutraceutical industries. The continuing rise in microbial resistance to traditional antibiotics has accelerated the need to find new anti-microbial agents.The potential applications of this research are in the pharmaceutical, veterinary pharmaceutical, clinical (with potential to treat MRSA), functional foods, value added products, and health supplements.
The multidisciplinary BPNR research team currently originally consisted of six fulltime academic staff members and seven researchers (Post-Doctoral, Postgraduate and Research Assistants). In 2006 S. McClean and M. Callaghan applied for Institute Research Status for their research group on cystic fibrosis which led to the formation of the Centre of Microbial Pathogenesis (CoMP). Both will continue to support the activities of the BPNR in the role of internal collaborators as they both have made significant contributions to the BPNR. The Centre is managed by Drs. J. Behan and M. Costello in a joint co-ordinating capacity.